OCTOBER 16-17, 2012
Sheraton Inner Harbor, Baltimore, MD
The Center for Medical Technology Policy (CMTP) is pleased to announce the 3rd Annual National Leadership Summit on Comparative Effectiveness Research Priorities, Methods and Policy. The two-day summit will focus on Diabetes and Related Conditions, diseases that according to the American Diabetes Association affect 8.3% of the US population. Thought leaders in comparative effective research (CER) will join key representatives from government, academia, industry, patient groups, professional organizations, payers, and the philanthropic sector. Summit participants will share expertise and identify methodological challenges and opportunities to collectively develop a strategic roadmap for CER, based on such themes as incorporating patient-reported outcomes into diabetes research, the comparative effectiveness of bariatric surgery and related therapies, and methodological recommendations for conducting future diabetes studies.
CMTP’s Summit in October 2011 focused on cardiovascular disease and attracted over 100 participants, speakers and thought leaders actively working in the field. Last year’s Summit agenda, available at: www.cmtpnet.org, shows the range of topics addressed by stakeholder groups represented at the Summit. The strategic roadmap for cardiovascular CER will be available for public comment and dissemination in the spring of 2012.
Intended Audience
The intended audience for the 2012 CER Summit will include individuals and organizations that fund, implement and use the results from diabetes-related CER. The Summit and the strategic roadmap will be developed to inform the decisions of organizations such as the Patient-Centered Outcomes Research Institute (PCORI), federal agencies, insurer health technology assessment groups, and pharmaceutical benefit managers, as well as clinicians and patients.
Planning Committee and Presenters
This year’s planning committee will be chaired by Dr. Fred Brancati, Professor of Medicine at Johns Hopkins University and Chief of the Division of General Internal Medicine at Johns Hopkins Hospital. Other planning committee members include:
- Dr. Ann Albright, PhD, RD, Director, Division of Diabetes Translation, Centers for Disease Control and Prevention
- Dr. Barbara Bartman, MD, MPH, Medical Officer, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality
- Dr. Judith Fradkin, MD, Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
- Dr. Bill Herman, MD, MPH, Director of the Michigan Diabetes Research and Training Center, University of Michigan
- Arnie Joseph, President and Founder, Chroma Multicultural Health
- Dr. Beth Koller, MD, Coverage and Analysis Group, Centers for Medicare and Medicaid Services
- Anna McCollister-Slipp, Diabetes Patient Advocate, Co-Founder of Galileo Analytics and Co-Founder of Patients, Inc.
- Dr. Maria Prince, MD, MPH, Medical Director, Office of Chronic Disease Prevention, Maryland Department of Health and Mental Hygiene
- Dr. Bob Ratner, MD, FACP, FACE, Chief Scientific and Medical Officer, American Diabetes Association
In addition to reaching out to the life sciences industries for sponsorship, we plan to engage business leaders and employers as they pay for much of the medical care related to diabetes and related conditions, including obesity. Many are already actively addressing these challenges and there is much to learn from them. We anticipate that this will result in a compelling program that concludes, as it did this year, with attendees inspired and optimistic about the use of CER to advance their mission.
Content
The Summit will use the results of cutting edge research from public health organizations, industry, public policy research, and academia as a background for developing a strategic roadmap for CER related to diabetes for the next three to five years. Speakers will be asked to present innovative concepts, methodological advances, industry forecasts, and best practices for conducting comparative effectiveness studies, and will be followed by robust discussions among the participants. Policymakers and regulators will provide insights on legislative, regulatory, rulemaking, budgetary developments, and new state and federal initiatives. Patient representatives will provide insights into what they consider the most important questions and patient related outcomes (PRO) for diabetes and related conditions. Additional potential topics of discussion include:
- Evidence gaps related to the comparative effectiveness of options to prevent, diagnose and treat diabetes;
- Methods available and needed to address these issues in different subgroups and settings (randomized controlled trials, registries, observational studies, use of consortia, environment intervention trials, policy trials, natural experiments);
- Stakeholder engagement, especially of patients, but also of policymakers, payers, and clinicians in CER.
- Selection of outcomes that meet stakeholders’ needs (intermediate outcomes, short term and long term clinical outcomes, patient reported outcomes);
- Coverage with Evidence Development (CED) and alternative mechanisms to fund new evidence synthesis.
- Translation of evidence into practice; and
- Strategic funding priorities.